Skip to content

HealthStream

US · HSTM #3266 by market cap
32.10 +0.79 +2.52%
Live - 5344 symbols - heartbeat 226s ago · 2026-10-08 08:03
Pre-market 32.37 +0.84%
After-hours 32.10 0.00%
Market cap
982.13M
P/B
2.75
EPS
0.61
Reader sentiment Are you bullish or bearish on HSTM?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
22.41 fair value ≈ 38.21 54.01
  • Implied fair-value range of 22.41-54.01, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -16.0% below the average-multiple fair value of 38.21.

Valuation each multiple against its own 5-year range

P/B ratio 2.75 Expensive vs history 95th percentile
5-year average 2.26 · #23 of 41 in Health Information Services
P/E ratio 44.58 Cheap vs history 28th percentile
5-year average 62.64 · forward 44.39 · #9 of 17 in Health Information Services
P/S ratio 3.06 Expensive vs history 80th percentile
5-year average 2.78 · forward 2.92 · #24 of 42 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
HealthStream (HSTM) 982.13M 44.58 2.75 0.41%
Veeva Systems (VEEV) 45.74B 46.31 6.15 0.00%
Tempus AI (TEM) 12.69B -48.85 28.53 0.00%
BrightSpring Health Services (BTSG) 12.62B 38.67 6.16 0.00%
Hinge Health (HNGE) 7.90B 73.14 22.93 0.00%
HealthEquity (HQY) 7.60B 33.18 3.82 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value34.00 Economic moatNone UncertaintyMedium

Trading 5.9% below Morningstar's fair value estimate.

Fair value

HealthStream Inc is assigned a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 6% discount to our quantitative fair value estimate of $34.00 per share; however, some caution is warranted due to this estimate's medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's solid growth bolsters our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its EPS 5-year growth of 21.6%, which ranks in the top 20% globally. The robust five-year track record of EPS growth is reason to be optimistic about the firm's shares. We believe this is a sign that shares could be cheap.

On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 0.9, for example, lies in the bottom 40% compared with peers globally. The market value of equity makes up a large fraction of enterprise value, indicating that shares have sharply risen, or that the company has a "lazy" balance sheet that is underleveraged. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-10-08 08:03:51 · For reference only, not investment advice and not tailored to your situation.